3 Caffeoylquinic Acid, 3-Caffeoylquinic Acid, Acid, 3-Caffeoylquinic, Acid, Chlorogenic, Chlorogenic Acid
Name | Chlorogenic acid | ||
PubChem CID | 1794427 | ||
Molecular Weight | 354.31g/mol | ||
Synonyms |
3 Caffeoylquinic Acid, 3-Caffeoylquinic Acid, Acid, 3-Caffeoylquinic, Acid, Chlorogenic, Chlorogenic Acid |
||
Formula | C₁₆H₁₈O₉ | ||
SMILES | C1C(C(C(CC1(C(=O)O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)O)O | ||
InChI | 1S/C16H18O9/c17-9-3-1-8(5-10(9)18)2-4-13(20)25-12-7-16(24,15(22)23)6-11(19)14(12)21/h1-5,11-12,14,17-19,21,24H,6-7H2,(H,22,23)/b4-2+/t11-,12-,14-,16+/m1/s1 | ||
InChIKey | CWVRJTMFETXNAD-JUHZACGLSA-N | ||
CAS Number | 327-97-9 | ||
ChEMBL ID | CHEMBL284616 | ||
ChEBI ID | CHEBI:16112 | ||
Drug Bank ID | DB12029 | ||
KEGG ID | C00852 | ||
Toxicity | Organism | Test Type | Route(Dose) |
rat | LD50 | intraperitoneal(165 mg/kg) | |
mouse | LD50 | intraperitoneal(254 mg/kg) | |
rat | LD50 | oral(322 mg/kg) | |
Structure |
Download
2D
MOL
3D
MOL
|
Chineses Pinyin | HuangQin | ||
Use Part | Root | ||
Habitat | HeiLongJiang, LiaoNing, NeiMengGu, HeBei, HeNan, GanSu, Shaanxi, ShanXi, ShanDong, SiChuan | ||
Flavor | Bitter | ||
Meridian Tropism | Lung, Gallbladder, Spleen, Large intestine, Small intestine | ||
Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Lamiales
-->Family: Lamiaceae
-->Genus: Scutellaria
-->Species: Scutellaria baicalensis
|
Chineses Pinyin | JiXueCao | ||
Use Part | Whole Herb With Root | ||
Habitat | Shaanxi, JiangSu, AnHui, ZheJiang, JiangXi, HuNan | ||
Flavor | Bitter, Pungent | ||
Meridian Tropism | Liver, Spleen, Kidney | ||
Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Apiales
-->Family: Apiaceae
-->Genus: Centella
-->Species: Centella asiatica
|
Chineses Pinyin | JinYinHua | ||
Use Part | Flower bud | ||
Habitat | JiangSu, ZheJiang, AnHui, FuJian, JiangXi, ShanDong, ShangHai, HeNan, HuNan, HuBei, GuangDong, GuangXi, HaiNan, SiChuan, GuiZhou, YunNan, XiZang, ChongQing, HeBei, ShanXi, LiaoNing, Shaanxi, GanSu | ||
Flavor | Sweet | ||
Meridian Tropism | Lung; Stomach; Heart | ||
Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Dipsacales
-->Family: Caprifoliaceae
-->Genus: Lonicera
-->Species: Lonicera japonica
|
Pair Name | Chlorogenic acid, Doxorubicin | |||
Partner Name | Doxorubicin | |||
Disease Info | [ICD-11: 2B51] | Osteosarcoma | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
Down-regulation | Phosphorylation | MAPK1 | hsa5594 | |
Down-regulation | Phosphorylation | MAPK3 | hsa5595 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
In Vitro Model | U2OS | Osteosarcoma | Homo sapiens (Human) | CVCL_0042 |
MG-63 | Osteosarcoma | Homo sapiens (Human) | CVCL_0426 | |
Result | These findings firstly propose CGA as a promising chemosensitizer and cardioprotective agent in OS therapy, suggesting the p44/42 MAPK pathway as relevantly involved in CGA-mediated Doxo susceptibility. |
Pair Name | Chlorogenic acid, Regorafenib | |||
Partner Name | Regorafenib | |||
Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Down-regulation | Expression | BCL2 | hsa596 | |
Down-regulation | Expression | BCL-xL | hsa598 | |
Up-regulation | Expression | CASP7 | hsa840 | |
In Vitro Model | PLC/PRF/5 | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0485 |
Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 | |
Result | This drug combination could be considered as a safe and more effective approach in HCC therapy. |
Pair Name | Chlorogenic acid, Fluorouracil | |||
Partner Name | Fluorouracil | |||
Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
Biological Phenomena | Induction-->ROS generation | |||
Gene Regulation | Down-regulation | Expression | MAPK1 | hsa5594 |
Down-regulation | Expression | MAPK3 | hsa5595 | |
In Vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 |
Hep 3B2.1-7 | Childhood hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0326 | |
Result | CGA sensitizes hepatocellular carcinoma cells to 5-FU treatment by the suppression of ERK activation through the overproduction of ROS. CGA has shown potential as a chemosensitizer of 5-FU chemotherapy in hepatocellular carcinoma. |
Pair Name | Chlorogenic acid, Methotrexate | |||
Partner Name | Methotrexate | |||
Disease Info | [ICD-11: 2B33.4] | Leukemia | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Down-regulation | Expression | BCL2 | hsa596 | |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Up-regulation | Cleavage | CASP9 | hsa842 | |
Down-regulation | Expression | COX2 | hsa4513 | |
Down-regulation | Expression | GPT | hsa2875 | |
Down-regulation | Expression | LDHA | hsa3939 | |
Down-regulation | Expression | NOS2 | hsa4843 | |
In Vivo Model | 6-8 weeks old Male Wistar rats (150-200 g) were use in this study. | |||
Result | These results imply that CGA has perfective effect against MTX-induced liver injury. Hence CGA supplementation might be helpful in abrogation of MTX toxicity. |
No. | Title | Href |
---|---|---|
1 | Protective effect of Chlorogenic acid against methotrexate induced oxidative stress, inflammation and apoptosis in rat liver: An experimental approach. Chem Biol Interact. 2017 Jun 25;272:80-91. doi: 10.1016/j.cbi.2017.05.002. | Click |
2 | Chlorogenic Acid Enhances Doxorubicin-Mediated Cytotoxic Effect in Osteosarcoma Cells. Int J Mol Sci. 2021 Aug 10;22(16):8586. doi: 10.3390/ijms22168586. | Click |
3 | Chlorogenic Acid Improves the Regorafenib Effects in Human Hepatocellular Carcinoma Cells. Int J Mol Sci. 2018 May 19;19(5):1518. doi: 10.3390/ijms19051518. | Click |
4 | Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases. Anticancer Drugs. 2015 Jun;26(5):540-6. doi: 10.1097/CAD.0000000000000218. | Click |